ESC Premium Access

Understanding and mitigating the risk of infection with canakinumab

Topic: Cardiovascular Pharmacotherapy, Other

Congress Session

About the speaker

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)
32 presentations
3 followers

8 more presentations in this session

Six-month treatment with novel oral anticoagulants ameliorates cerebral blood flow, as evaluated with brain perfusion SPECT.

Speaker: Doctor H. Takeuchi (Ogachi, JP)

Thumbnail

TAFI level dynamics during long-term warfarin therapy as a predictor of recurrent bleedings in a target INR

Speaker: Professor N. Vorobyeva (Moscow, RU)

Thumbnail

Pharmacokinetics and pharmacodynamics of alirocumab in patients with autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function or ApoB loss-of-function mutations

Speaker: Doctor M. Krempf (Nantes, FR)

Thumbnail

Evaluation of the pharmacokinetics and pharmacodynamics of subcutaneously administered dutogliptin for daily injection with granulocyte colony stimulating factor (G-CSF) for AMI

Speaker: Mr D. Nix (Lexington Township, US)

Thumbnail

Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results

Speaker: Doctor M. Bonaca (Aurora, US)

Thumbnail

Access the full session

Innovative drug therapies

Speakers: Professor P. Libby, Doctor H. Takeuchi, Professor N. Vorobyeva, Doctor M. Krempf, Mr D. Nix...
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

This platform is supported by

logo Novo Nordisk